Abstract
Introduction Worldwide, pancreatic cancer has a poor prognosis. Early diagnosis may improve survival by enabling curative treatment. Statistical and machine learning diagnostic prediction models using risk factors such as patient demographics and blood tests are being developed for clinical use to improve early diagnosis. One example is the Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) model, which employs patients’ age, blood glucose and weight changes to provide pancreatic cancer risk scores. These values are routinely collected in primary care in the United Kingdom (UK). Primary care’s central role in cancer diagnosis makes it an ideal setting to implement ENDPAC but it has yet to be used in clinical settings. This study aims to determine the feasibility of applying ENDPAC to data held by UK primary care practices.
Methods and analysis This will be a multi-centre observational study with a cohort design, determining the feasibility of applying ENDPAC in UK primary care. We will develop software to search, extract and process anonymised data from 20 primary care providers’ electronic patient record management systems on participants aged 50+ years, with a glycated haemoglobin (HbA1c) test result of ≥ 48 mmol/mol (6.5 %) and no previous abnormal HbA1c results. Software to calculate ENDPAC scores will be developed, and descriptive statistics used to summarise the cohort’s demographics and assess data quality. Findings will inform the development of a future UK clinical trial to test ENDPAC’s effectiveness for the early detection of pancreatic cancer.
Ethics and dissemination This project has been reviewed by the University of Surrey University Ethics Committee and received a favourable ethical opinion (FHMS 22-23 151 EGA). Study findings will be presented at scientific meetings and published in international peer-reviewed journals. Participating primary care practices, clinical leads and policy makers will be provided with summaries of the findings.
Strengths and limitations of this study’s methods
Early computerisation of UK primary care, incorporating linkage to pathology systems combined with pay-for-performance for chronic disease management including diabetes, helps to ensure population-wide data.
The extraction software will permit validation of the extracted data by primary care staff prior to transfer to the research team.
Using HbA1c results only to define new-onset diabetes means this study is not impacted by the quality of diabetes diagnosis coding in primary care.
This study will raise awareness of new-onset diabetes’ association with pancreatic cancer within the primary care community.
The study period includes the COVID-19 pandemic, thus the data within this period may not reflect data obtained before or after the pandemic.
Competing Interest Statement
JT's role in Surrey and Sussex Cancer Alliance is part funded by Cancer Research UK.
Funding Statement
This research was conducted as part of a PhD studentship funded by the University of Surrey and undertaken by HC (Grant no.: NA). This study received seed funding from the Faculty of Health and Medical Sciences, University of Surrey awarded to AL (Grant no.: NA).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University Ethics Committee of the University of Surrey gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Revisions as a result of peer review: - More information on the patient and public involvement section - Details about the sample size justification - Impact of COVID-19 on the study - Make the complexity of the study more apparent in the abstract - Provide HbA1c in both percentage and mmol/mol where relevant - Figure of the flow of data and processes in the study - General rearranging and rewording of portions of text to improve readability and clarity of the protocol.
Data Availability
Data extracts created as part of this project will remain under the management of GP practices. Data will not be made open access or deposited in any repository, as outlined in the data sharing agreement. Subject to all necessary approvals, data may be made available for secondary use by the GP practices who remain data controllers.
